A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses.
Level 1 - systematic review of randomized trials
Umbrella review of systematic reviews and meta-analyses
PubMed 38096722 · doi:10.1016/j.psychres.2023.115626
What was done
The authors conducted an umbrella review and systematic evidence map of systematic reviews and meta-analyses assessing the association between cannabis use and psychosis-related outcomes across healthy, clinical high-risk, and diagnosed clinical populations. Methodological quality of included reviews was evaluated using AMSTAR-2.
What was found
A total of 32 systematic reviews and meta-analyses were analyzed. The abstract provides no quantitative effect sizes or statistics. Evidence indicates cannabis use is associated with subclinical psychosis states, schizotypal traits, earlier onset, and development of psychosis in healthy populations, as well as relapse in patients with psychotic disorders. Associations with clinical high-risk states, attenuated psychosis symptoms, and transition to psychosis were not confirmed.
Why it matters
This umbrella review maps existing meta-analytic evidence across the full psychosis continuum, delineating where associations are documented versus where evidence remains insufficient or unconfirmed.
Limits
The abstract provides no numerical data, odds ratios, or AMSTAR-2 quality scores. The synthesized evidence relies on observational research, and the authors state that whether causal effects underlie these associations has not been sufficiently addressed.
Cited by
- supports Cannabis consumption can trigger permanent psychosis or severe psychotic episodes in individuals predisposed to psychosis or bipolar disorder.